Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612348 | 0.86 | PKM (0.46) | HPGDHSD17B10L3MBTL1TLR9TLR8 | |
| SCHEMBL29721053 | 0.80 | LMNA (0.42) | HPGDHSD17B10L3MBTL1TLR9TLR8 | |
| SCHEMBL30816887 | 0.79 | FFAR4 (0.39) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL29530566 | 0.77 | HSD11B1 (0.48) | KDM1AGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL21409353 | 0.77 | NR3C1 (0.41) | KDM1AGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL29384321 | 0.77 | KMT2A (0.42) | HPGDHSD17B10L3MBTL1DRD2TLR9 | |
| SCHEMBL30019792 | 0.76 | RBP4 (0.41) | HPGDHSD17B10L3MBTL1TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL31138071 | 0.76 | NR3C1 (0.41) | KDM1AGABRDGABRA1GABRB1GABRA5 | |
| SCHEMBL30267336 | 0.75 | LRRK2 (0.41) | HPGDHSD17B10L3MBTL1LRRK2 | |
| SCHEMBL30266965 | 0.75 | GABRD (0.51) | GABRDGABRA1GABRB1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2025-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | BTK, ABL1, LYN | KDM1A 731/4885GABRD 2412/4885GABRA1 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.